Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome

Izumi Mori, Christophe Parizot, Karim Dorgham et al. · 2008

Read Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome by Izumi Mori, Christophe Parizot, Karim Dorgham et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002109.txt.

Description

Izumi Mori and co-authors found an early blood sign that tracks recovery in a nerve illness, in a 2008 PLOS ONE study. Guillain-Barre syndrome is a sudden paralysis caused by the immune system attacking nerves. High doses of pooled antibodies, called intravenous immunoglobulin, are commonly used to treat it and many autoimmune diseases. Yet how they work is only partly explained, and no early marker predicted their efficacy.

The team report that prominent plasmacytosis, a surge of antibody-making cells in blood after the treatment, correlates with clinical improvement. An early marker lets doctors switch tactics sooner when a costly therapy is failing.

Catalog record

CREATORIzumi Mori, Christophe Parizot, Karim Dorgham et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002109

Browse the full library · About the Tower of Babel